Nortriptyline-moclobemide

From Psychiatrienet
Revision as of 16:31, 28 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from nortriptyline to moclobemide.[1] [2]

Nietinrijdenbord.png Stop nortriptyline
  • Before day 1: gradually reduce dosage of nortriptyline to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • Day 1-3: reduce dosage of nortriptyline to 25 mg/day.
  • Day 4-7: reduce dosage of nortriptyline to 10 mg/day.
  • Day 8: stop administration of nortriptyline.
Eenrichtingbord.png Start moclobemide
  • Day 8-22: a wash-out period of 2 weeks is necessary.
  • Day 23: start administration of moclobemide in a dosage of 150 mg/day.
  • Day 28: increase dosage of moclobemide to 300 mg/day.
Letopbord.png Cave


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.